Abstract 5015
Background
Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers in china. Because the disease often has no symptoms in the early stages, it is usually detected at a more advanced stage that is more challenging to treat. The inter-communication between esophageal squamous cell carcinoma and its surrounding microenvironment is essential for tumor progression and metastasis. Exosome plays a key role in information delivery between primary lesion and pre-metastatic niche via its packed bioactive molecules. The aim of this study is to explore the effect of exosome from tumor plasma to angiogenesis in human lymphatic endothelial cells (HLEC) in vitro.
Methods
Total circulation exosomes (CEs) were extracted and purified to selectively capture EpCAM positive exosomes by magnetic-bead technique. Proteins were separated by SDS-PAGE, and protein bands were analyzed by mass spectrometry. Tube formation assay and fluorescence imaging assay were performed in vitro.
Results
The expression level of CEs in ESCC patients with lymph node metastasis were significantly higher than that in ESCC patients without metastasis and healthy control group (respectively; P < 0.001). The tumor associated exosomes could be taken by HLEC and its transferred into HLECs could to promote HLECs tube formation in vitro. In addition, the mass spectrometry was used to analysis the proteomic content in tumor associated exosomes, tumor-related proteins such as matrix-metalloproteinases, PP2A proteins and EIF proteins were identified in the exosome.
Conclusions
Exosomes released by ESCC may play important roles in the microenvironment of ESCC and provide a potential application of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
NSFC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2935 - Correlation of progression free survival-2 and overall survival in solid tumors
Presenter: Paul Mainwaring
Session: Poster Display session 1
Resources:
Abstract
2273 - High performance of serial tumor biopsies in first in human (FIH) phase I trials.
Presenter: Jun Sato
Session: Poster Display session 1
Resources:
Abstract
5933 - Response rates and lesion-level progression patterns of solid tumor patients in an academic phase 1 program: implications for tumor heterogeneity
Presenter: Christopher Chen
Session: Poster Display session 1
Resources:
Abstract
3569 - Clinical Benefit and Response Rate in Early Phase Clinical Trials: First Report from a Single-Institution Study
Presenter: Antonio Marra
Session: Poster Display session 1
Resources:
Abstract
4139 - Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): a single Phase I Unit experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
4451 - Improving patient selection for immuno-oncology phase 1 trials: an external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O).
Presenter: Ghassan Al Darazi
Session: Poster Display session 1
Resources:
Abstract
1696 - Demonstrating the Changing Trends in Phase 1 Clinical Trials
Presenter: Christina Guo
Session: Poster Display session 1
Resources:
Abstract
3202 - Participation of Women in phase 1 oncology clinical trials
Presenter: Laura Vidal
Session: Poster Display session 1
Resources:
Abstract
4518 - Predictors for early trial discontinuation of patients with cancer participating in phase I clinical trials
Presenter: Joeri Douma
Session: Poster Display session 1
Resources:
Abstract
4368 - Safety of Tumor Treating Fields delivery to the torso: Meta analysis from TTFields clinical trials
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract